RLFTF trades lower Monday after putting together gains last week.
As of 1:55 RLFTF is trading at .20 down .018 losing 8% on the day. 3.6 million shares have traded which is a little lighter than average. RLFTF opened down about 10% and has traded in a narrow range between .1992 and .2045.
RLFTF Initiates Clinical Trial
Applied Pharma Research initiated a pivotal clinical trial with Relief Therapeutics’ novel nasal spray
- The trial is designed to evaluate the efficacy and safety of the product in reducing viral load in the upper respiratory airways in recently infected individuals.
- RLFTF its lead compound RLF-100TM (aviptadil) in advanced clinical development to treat COVID-19-induced lung injury
“We are very happy to see the start of this pivotal clinical trial with one of the main product candidates in APR’s portfolio so shortly after we signed the binding term sheet to acquire all shares of this exciting company,” Jack Weinstein, Chief Financial Officer and Treasurer of Relief said.
Recent Stock Performance
|+/- EMA(20)||0.23 (-13.04%)|
|+/- SMA(50)||0.27 (-25.93%)|
|+/- SMA(200)||0.42 (-52.38%)|
|CCI20||-43.8743||Neutral||Chaikin Money Flow||0.2173||Buy|
|MACD||-0.0301||Sell||Money Flow Index||24.2603||Sell|
|STOCH (14,3)||48.6521||Buy||STOCH RSI||1.0000||OverBought|